Healthcare - Biotechnology - NASDAQ - US
$ 3.345
-6.95 %
$ 439 M
Market Cap
-1.54
P/E
CASH FLOW STATEMENT
-165 M
OPERATING CASH FLOW
18.7 M
INVESTING CASH FLOW
655 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Prime Medicine, Inc.
| Net Income | -198 M |
| Depreciation & Amortization | 4.65 M |
| Capital Expenditures | -8.72 M |
| Stock-Based Compensation | 13.9 M |
| Change in Working Capital | 2.65 M |
| Others | 5.3 M |
| Free Cash Flow | -174 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (198.1) | (121.8) | (165.4) | (3.4) | (2.5) |
| Depreciation & Amortization | 4.7 | 2.2 | 0.6 | 43 K | 0 |
| Deferred Income Tax | (0.3) | (1.0) | (0.6) | 1.9 | 0 |
| Stock Based Compensation | 13.9 | 6.5 | 1.7 | 0.4 | 0 |
| Other Operating Activities | 11.8 | 17.7 | 98.4 | (4.6) | 0.7 |
| Change in Working Capital | 2.6 | (35.4) | 31.2 | 0.2 | 0.5 |
| Cash From Operations | (165.4) | (131.8) | (34.1) | (5.5) | (1.3) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (8.7) | (16.1) | (4.2) | (0.6) | 0 |
| Other Items | 27.4 | (31.0) | (69.5) | (0.4) | 0 |
| Cash From Investing Activities | 18.7 | (47.1) | (73.6) | (1.1) | 0 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.7 | (3.8) | 269.3 | 34.9 | 10.0 |
| Cash From Financing Activities | 0.7 | 181.5 | 269.3 | 34.9 | 10.0 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (146.0) | 2.6 | 161.6 | 28.3 | 8.6 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (174.1) | (147.9) | (38.2) | (6.2) | (1.3) |